Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
Breast cancer patients often receive systemic drugs as the initial curative treatment of
their disease. The initial systemic therapy leads to a variable degree of tumor shrinkage. At
present, there is no evidence-based consensus among breast surgeons on the optimal extent of
resection after considerable tumor shrinkage and whether resection margin should be designed
according to the tumor extent before treatment or the extent after treatment. This trial will
help determine the optimal extent of resection in tumors that exhibits a significant change
in volume after primary systemic therapy.